



# Brucellosis EU NRL Activities 2014 report to the EU Brucellosis EURL

**Country:**-----

<p><b>Head of NRL:</b> -----</p> <p>E mail address: -----</p> <p>Phone number: -----</p> <p><b>Contact Person:</b> -----</p> <p>E mail address: -----</p> <p>Phone number: -----</p>
--

**Organization:** **PRE-FILLED PAGE**-----

-----

**Address:**-----

-----

-----

Phone #:-----Fax #:-----

E mail address :-----

Website: -----

---



**I-General information**

**1-Your NRL is:**

- a central lab with a network of local diagnostic labs with only confirmatory analyses
- plays also the role of a routine diagnostic lab for the region or the whole country (1<sup>st</sup> line laboratory + confirmation)
- working in brucellosis serology/ bacteriology / molecular biology
- diagnosis of brucellosis in humans/ domestics animals/ wildlife
- other activities : R&D, expertise, official control, diagnostic reagents production, vaccine production, reagents control, vaccine control

**2-Key figures of your network**

Parameter	Number of labs
<b>Number of local diagnostic labs within your national network</b>	
-Working only in serology	
-Working in serology and bacteriology	
-Working in serology and molecular biology	
-Working in serology, bacteriology and molecular biology	

**3-Tests used for the serological surveillance:**

Species	Free country status (Y/N)	Screening S (number) and / or confirmation C (number)					
		RBT	CFT	SAT	iELISA	cELISA	other
Cattle							
Small ruminants							
Pigs							
Wildlife							

**4-Use of vaccination:**

Species	Vaccination (Y/N)	Type of vaccine
Cattle		
Small ruminants		
Pigs		
Wildlife		

**Any evolution you want to underline compared to last year?**



**II-Activities of NRL**

**1-Interlaboratory proficiency test (ILPT)**

**1.1-Number of ILPTs organized this year and methods :**

Methods	Serology		Bacteriology		Molecular biology		Other :
	Milk	Serum	Strains	Tissues	DNA	Strains	
Cattle							
Small ruminants							
Pigs							
Wildlife							
Other species							

**1.2-For each ILPT organized by your NRL, please specify the methods and the number of participating labs:**

ILPT	Methods (number of participants)
1	
2	
3	
4	

**1.3-Measures taken to address low performances**

- No specific measures
- Follow-up studies or on site visits to few NRLs
- 100 % follow-up

**Please describe shortly follow-up measures for underperforming labs**

**2-Training sessions**

**2.1-Number of training sessions organized this year and methods :**

Nber of sessions	Serology		Bacteriology		Molecular biology		Other :
	technical exercise	theoretical aspects	technical exercise	theoretical aspects	technical exercise	theoretical aspects	



**2.2-For each training session organized by your NRL, please specify the training duration (number of days), the main topics and the number of trainees:**

Training session	Duration (d)	Topics (number of trainees)
1		
2		
3		
4		

**2.3-Documents provided during training**

- No document  
-Internal documents  
-International standards

**Please describe shortly the documents used during training (SOPs, booklet, posters, EU directives, OIE manual....)**

**3-*Brucella* strains collected in the report period**

<b><i>Brucella</i> strains isolated and/or biotyped</b>	<b>Animal species</b>	<b>Country of origin</b>	<b>Species</b>	<b>Biovar</b>	<b>Quantity</b>
Animal strains					
Human strains					
Unknown origin					

**4-Biologicals control**

**4.1-Control of reagents in your country**

- No control  
-A part of reagents are controlled  
-All reagents are controlled (at least one batch / reagent)



#### 4.2-Please specify your control activity for reagents in the report period

Reagent	Reagents usually controlled in the lab (Y/N)	Standard serum used Y/N and name of the serum	Number of batches controlled during the period
RBT antigen			
CFT antigen			
SAT antigen			
MRT antigen			
iELISA kits (serum)			
iELISA kits (milk)			
Control sera			
Brucellin			

#### 4.3. Vaccines controlled at this laboratory (acc. to OIE requirements)

Vaccine	No. batches controlled	Trademark
Rev.1		
S19		
RB51		

#### 5-Scientific activities in the report period

Number of publications	Serology	Bacteriology – Molecular biology	Others:
Posters or oral communications in national meetings			
Posters or oral communications in international meetings			
Professional papers			
Papers in peer-reviewed journals			



### III-Expectations toward EURL activities

1-What are the areas of your EURL’s activity, if any, you deem comparatively overweighed or underweighed?

Activities	underweighed	well balanced	overweighed
A1 : Support to NRLs			
A2 : Interlaboratory ring trials			
A3 : NRLs network related training activities and animation			
A4 : Development, evaluation of innovative analytical methods			

**Please suggest any activity to be developed or reinforced**

2-How do you rate the overall quality (timeliness, independence of judgment, completeness, etc.) and usefulness of EURL scientific advice reports/ guidance documents/ research reports in general?

- 5 constitutes the highest quality and 1 the lowest quality -

	1	2	3	4	5
timeliness					
independence of judgment					
completeness					
usefulness					
overall cooperation with EURL					

3 -Overall, is the quality/quantity of activities (e.g. reference materials, technical advice, training exercises) and guidance documents produced by your EURL in line with your expectations?

- Yes
- No

4 - Do you feel adequately informed about the EURL’s activities?

- Yes
- No

*Any suggestions to improve the NRLs network activities !*